AfricaRegulatory

African Pharmaceutical Regulatory Intelligence

RIFAXIMIN 200.000 Mg ;

10 registrations across 1 African market— 10 active

Markets with RIFAXIMIN 200.000 Mg ;

Recent registrations

Brand / ProductMarketHolderStatusExpires
Biorefamin 200
Film Coated Tablets
🇪🇬EgyptInnova vitae pharmaactive
Traveria 200 mg
Film Coated Tablets
🇪🇬EgyptWestern Pharmaceuticals Industriesactive
FATROXIM 200 mg
Film Coated Tablets
🇪🇬EgyptATM Pharmaceutical Industries, Import and Exportactive
RIFAXIMIN
Film Coated Tablets
🇪🇬EgyptTherapeutica Pharmaceuticalsactive
Biofaximin 200 mg
Film Coated Tablets
🇪🇬EgyptSAJA Pharmaceuticals Egypt - SAJAactive
IDIBACT 200mg
Film Coated Tablets
🇪🇬EgyptKhufu Pharma for pharmaceutical Industriesactive
Biofaximin 200 mg
Film Coated Tablets
🇪🇬EgyptSAJA Pharmaceuticals Egypt - SAJAactive
RIFAXIMIN
Film Coated Tablets
🇪🇬EgyptTherapeutica Pharmaceuticalsactive
GASTROBIOTIC 200 mg
Film Coated Tablets
🇪🇬Egyptal andalous for pharmaceutical industriesactive
Biorefamin 200
Film Coated Tablets
🇪🇬EgyptInnova vitae pharmaactive

RIFAXIMIN 200.000 Mg ; in Africa — Regulatory Overview

RIFAXIMIN 200.000 Mg ; is registered across 1 African markets with 10 total product registrations on file. Data is sourced directly from official national drug regulatory authorities including Egypt. AfricaRegulatory refreshes this data daily from official government sources.

Of the 10 registrations, 10 (100%) are currently active. Regulatory affairs teams use AfricaRegulatory to track registration expiry dates, identify market incumbents, and monitor approval status across African markets without manual monitoring of each national regulator.